Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Hometown of Laura Ingalls Wilder set for a growth spurt
DE SMET, S.D. (AP) — A rural South Dakota county known mainly as the former home of beloved author L2024-05-22Jon Bon Jovi, 62, hints he's been with 100 women
Rock legend Jon Bon Jovi has had his fair share of dalliances. The rocker, 62, implied he had been w2024-05-22General Hospital's Nancy Lee Grahn defends former co
General Hospital star Nancy Lee Grahn has come to the defense of her former onscreen daughter, Haley2024-05-22Baywatch star Jeremy Jackson's ex
Former model Loni Willison has been spotted hauling round a shopping cart filled with her possession2024-05-22- NEW YORK (AP) — Ty France hit a go-ahead RBI single in Seattle’s four-run ninth inning against relie2024-05-22
- NEW YORK (AP) — The pro-Palestinian demonstration that paralyzed Columbia University ended in dramat2024-05-22
atest comment